Successful completion of the ID-ALS study Part 1: genetic testing of 1.000 people with ALS in Germany

The first part of the ID-ALS study to identify genetic alterations in people with amyotrophic lateral sclerosis (ALS) was successfully completed by Ambulanzpartner on 30.10.2022. In the study

Algorithm-based recommendations in ALS – Presentation at Neurowoche 2022

At the Neurowoche 2022 together with the congress of the German Society for Neurology (DGN) in Berlin, our first experiences with the use of algorithm-based care recommendations as decision

Scientific publication on recording the course of the disease with the ALS app

The recording of the course of the disease amyotrophic lateral sclerosis (ALS) with the help of the ALS Functional Scale (ALSFRS-R) is of great relevance for those affected themselves, the ALS

New functions for the supply of aids and medicines in the ALS app

We are constantly developing the ALS app with innovative ideas and feedback from our users. The latest version of the ALS app with new functions is available for download free of charge from the

The ALS app supports the first genetic therapy for ALS with mutation in the SOD1 gene.

Since March 2022, two patients have been treated with the drug Tofersen at the ALS outpatient clinic of the Charité in Berlin. The documentation and monitoring of the course of treatment are